12,372 trials
Herpes Zoster
Primary: Geometric Mean Titre (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks Post-vaccination — 395.3; 391.7 gpELISA units/mL — p=<0.001
Breast Cancer
Primary: Disease Free Survival. — 81.0; 79.6 percentage of patients
Migraine Disorders
Primary: Percentage of Participants With Headache Relief at 60 Minutes Post Dose(Migraine) or 30 Minutes Post Dose(Cluster Headache) — 93.9; 93.9; 93.9 Percentage of participants
Influenza, Human
Primary: Time to Clinical Response (TTCR) in Participants With Confirmed Influenza — 5.87; 5.14; 5.63 Days — p=0.25
Dry Eye Syndromes
Primary: Change From Baseline in the Ocular Surface Disease Index© (OSDI©) Score — 41.12; 39.63; -15.61; -13.16 score on a scale
Diabetes · Diabetes Mellitus, Type 2
Primary: Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke…
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events — 768; 436; 287; 4 participants
Prevention of CMV Infection or Disease
Primary: Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant — 37.5; 60.6 Percentage of participants — p=<0.0001
Congenital Bleeding Disorder · Haemophilia B
Primary: Incidence of Inhibitory Antibodies Against Coagulation Factor IX (FIX) Defined as Titre Above or Equal to 0.6 Bethesda Units (BU) — 0; 0 Participants
Congestive Heart Failure
Primary: Urine Output — 1636; 1515 mL
Hepatitis C Virus Infection · Human Immunodeficiency Virus Infection · Chronic Hepatitis C
Primary: Percentage of Participants in GT1 Analysis Group 1 in Part 2 Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) — 97.0 percentage of participants
Hypopituitarism
Primary: BOLD Signal Measured by Functional MRI Scan to Functional Connectivity Measured by fMRI
Seborrheic Keratosis
Primary: Proportion of Subjects With Lesion Clearance — 16 Participants
Attention Deficit Hyperactivity Disorder
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) — -22.9; -20.8 units on a scale
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 96.4; 96.3 percentage of participants — p=<0.001